IXT-006

IXT-006 is an investigational respiratory therapy being developed by invoX Pharma for the treatment of chronic obstructive pulmonary disease (COPD). The drug is formulated for delivery via the proprietary Softhaler® platform, a dry powder inhalation (DPI) technology designed to optimize the delivery of active ingredients directly to the lungs. While the specific molecular target and the nature of the active ingredient (whether a small molecule or a biologic) have not been publicly disclosed, IXT-006 is part of a broader pipeline of inhaled candidates leveraging the Softhaler® technology to address high unmet needs in pulmonary medicine. The company's research scope for this platform includes the delivery of various biological molecules such as peptides, nucleic acids, enzymes, and antibodies.